Incidence of Pneumocystis Pneumonia in Immunocompromised Patients without Human Immunodeficiency Virus on Intravenous Pentamidine Prophylaxis: A Systematic Review and Meta-Analysis.
Chia-Yu ChiuPatrick R ChingPublished in: Journal of fungi (Basel, Switzerland) (2023)
Monthly IVP is an appropriate second-line agent for PCP prophylaxis in certain non-HIV immunocompromised hosts, especially in patients with hematologic malignancies and hematopoietic stem cell transplant recipients. Using IVP for PCP prophylaxis as an alternative to oral TMP-SMX while patients are unable to tolerate enteral medication administration is feasible.
Keyphrases
- human immunodeficiency virus
- end stage renal disease
- antiretroviral therapy
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- emergency department
- prognostic factors
- hematopoietic stem cell
- risk factors
- low dose
- hiv positive
- intensive care unit
- patient reported
- patient reported outcomes
- hiv aids
- hiv testing
- adverse drug